This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaneda, A. Articles by Feinberg, A. P. Search for Related Content PubMed PubMed Citation Articles by Kaneda, A. Articles by Feinberg, A. P. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Genetics and Biomarkers

Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk

Division of Molecular Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Andrew P. Feinberg, Departments of Medicine, Oncology, and Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Ross 1064, 720 Rutland Avenue, Baltimore, MD 21205. Phone: 410-614-3489; Fax: 410-614-9819; E-mail: afeinberg{at}jhu.edu.

Epigenetic alterations in cancer occur at least as commonly as genetic mutations, but epigenetic alterations could occur secondarily to the tumor process itself. To establish a causal role of epigenetic changes, investigators have turned to genetically engineered mouse models. Here, we review a recent study showing that a mouse model of loss of imprinting (LOI) of the insulin-like growth factor II gene (Igf2), which shows aberrant activation of the normally silent maternal allele, modifies the risk of intestinal neoplasia caused by mutations of the adenomatous polyposis coli (Apc) gene. This increased risk corresponds to the apparent increased risk of colorectal cancer in patients with LOI of IGF2. The model suggests that preexisting epigenetic alterations in normal cells increase tumor risk by expanding the target cell population and/or modulating the effect of subsequent genetic alterations on these cells, providing a novel idea for cancer risk management. (Cancer Res 2005; 65(24): 11236-40)

This article has been cited by other articles:

				X. Cheng Silent Assassin: Oncogenic Ras Directs Epigenetic Inactivation of Target Genes Sci. Signal., April 1, 2008; 1(13): pe14 - pe14. [Abstract] [Full Text] [PDF]

				M. Esteller Epigenetics in Cancer N. Engl. J. Med., March 13, 2008; 358(11): 1148 - 1159. [Full Text] [PDF]

				A. Kaneda, C. J. Wang, R. Cheong, W. Timp, P. Onyango, B. Wen, C. A. Iacobuzio-Donahue, R. Ohlsson, R. Andraos, M. A. Pearson, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk PNAS, December 26, 2007; 104(52): 20926 - 20931. [Abstract] [Full Text] [PDF]

				C.-Q. Zhu, S. N. Popova, E. R. S. Brown, D. Barsyte-Lovejoy, R. Navab, W. Shih, M. Li, M. Lu, I. Jurisica, L. Z. Penn, et al. Integrin {alpha}11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells PNAS, July 10, 2007; 104(28): 11754 - 11759. [Abstract] [Full Text] [PDF]

				A. H. Ting, K. M. McGarvey, and S. B. Baylin The cancer epigenome--components and functional correlates Genes & Dev., December 1, 2006; 20(23): 3215 - 3231. [Abstract] [Full Text] [PDF]

				F. J. Sim, H. M. Keyoung, J. E. Goldman, D. K. Kim, H.-W. Jung, N. S. Roy, and S. A. Goldman Neurocytoma Is a Tumor of Adult Neuronal Progenitor Cells J. Neurosci., November 29, 2006; 26(48): 12544 - 12555. [Abstract] [Full Text] [PDF]

				D. Barsyte-Lovejoy, S. K. Lau, P. C. Boutros, F. Khosravi, I. Jurisica, I. L. Andrulis, M. S. Tsao, and L. Z. Penn The c-Myc Oncogene Directly Induces the H19 Noncoding RNA by Allele-Specific Binding to Potentiate Tumorigenesis. Cancer Res., May 15, 2006; 66(10): 5330 - 5337. [Abstract] [Full Text] [PDF]